Increasing technological advancements is expected to bolster the gene synthesis market

Publisher: The Insight Partners

The advancement in the field of the healthcare and research industry is driving the prominent players in this market for more research and developments for the gene synthesis market. The key players in the market such as GenScript, in June 2018, invest US$75 million for the establishment of biologics discovery, development, clinical and commercial manufacturing center in the city of Zhenjiang, Jiangsu Province, China. The Manufacturing Center will be in use by 2020.

Some of the key players operating the global gene synthesis market include Thermo Fisher Scientific Inc, Integrated DNA Technologies, Inc., Twist Bioscience, OriGene Technologies, Inc., BioCat GmbH, GenScript, Eurofins Scientific, Bioneer Corporation, ATUM, GENEWIZ and among others.

In the recent years, gene synthesis market has progressed significantly. The global market for gene synthesis is anticipated to grow from US$ 2,866.1 Mn in 2017 to US$ 20,122.3 by 2025 at a CAGR of 28.7%. The rising technological advancements in the biotechnology has increased, especially in the field of gene synthesis.

The advancement in the gene synthesis has led to the faster and easier design of DNA, and helped exponentially reducing the cost of DNA sequencing and synthesis. The increasing life science research mainly in molecular separation technology and protein purification expected to boost the growth of the market. However, the long time consuming approval phase of the research is expected to act as major challenges hindering the market growth.

Many industry players have come up with innovative types of gene synthesis in last few years. The increasing adoption of advanced techniques are increasing the demand for the gene synthesis market in the forecast period. The techniques such as cloning, gene sequencing, genome engineering has results into the generation of genetically modified organisms. Additionally, the investments from public and private investors are also help to rising for the gene synthesis and enabling technological developments and standard biological parts. For instance, in April 2015, Twist Bioscience, launched an alpha manufacturing program for the production of synthetic genes using the proprietary silicon-based DNA synthesis platform.